

---

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**Form 8-K**

---

**Current Report**  
**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**June 23, 2021**

**Date of Report**

**(Date of earliest event reported)**

---

**DURECT CORPORATION**  
**(Exact name of Registrant as specified in its charter)**

---

**Delaware**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**000-31615**  
**(Commission**  
**File Number)**

**94-3297098**  
**(I.R.S. Employer**  
**Identification No.)**

**10260 Bubb Road**  
**Cupertino, CA 95014**  
**(Address of principal executive offices) (Zip code)**

**(408) 777-1417**  
**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class  
Common Stock \$0.0001 par value per share

Trading Symbol  
DRRX

Name of Each Exchange on Which Registered  
The NASDAQ Stock Market LLC  
(The Nasdaq Capital Market)

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

### **Item 8.01 Other Events**

On June 23, 2021, DURECT Corporation issued a press release announcing the presentation of additional clinical data from a DUR-928 Phase 1b trial in non-alcoholic steatohepatitis (NASH) and a Phase 1 trial in subjects with hepatic impairment (HI) as part of two posters at the 2021 International Liver Conference (EASL) being held virtually June 23-26, 2021. A copy of the press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

### **Item 9.01 Financial Statements and Exhibits**

#### **(d) Exhibits**

99.1 [Press Release of DURECT Corporation dated June 23, 2021](#)

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 23, 2021

**DURECT Corporation**

By: /s/ James E. Brown

James E. Brown

President and Chief Executive Officer

## DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)

*New Data Further Supports DUR-928's Potential in Acute and Chronic as well as Moderate and Severe Liver Disease*

CUPERTINO, Calif., June 23, 2021, -- [DURECT Corporation](#) (Nasdaq: DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase 1b trial in non-alcoholic steatohepatitis (NASH) and a Phase 1 trial in subjects with hepatic impairment (HI) as part of two posters at the 2021 [International Liver Conference \(EASL\)](#) being held virtually June 23-26, 2021.

“We are pleased to report additional signals of potential efficacy from our Phase 1b NASH trial of DUR-928, our lead epigenetic regulator” said James E. Brown, D.V.M., President and CEO of DURECT. “The roughly 20% median reduction from baseline of HOMA-IR, an important indicator of insulin resistance, observed after only 4 weeks of daily oral administration at the 50 mg and 150 mg dose levels, is similar to the level of reductions seen in longer term studies of several well-established diabetes therapeutics. In addition, the Phase 1 trial in subjects with moderate and severe hepatic function impairment further demonstrates DUR-928’s safety and potential efficacy profile in subjects with serious liver disease. We continue to make progress opening new clinical trial sites and enrolling patients in our ongoing AHFIRM Phase 2b trial in alcohol-associated hepatitis (AH) patients while we determine next steps for DUR-928 in NASH and explore additional potential acute and chronic indications.”

Poster #1198 entitled “Efficacy Signals of 4-Week Oral DUR-928 in NASH Subjects,” presented by Eric Lawitz, M.D., Vice President, Scientific and Research Development, Texas Liver Institute, disclosed additional potential efficacy signals from DURECT’s Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients. Key highlights include:

- **Improvement from baseline in insulin resistance** as assessed by the homeostatic model assessment (HOMA-IR). Subjects in the 50 mg and 150 mg groups had 22% and 18% median reductions (not statistically significant) of HOMA-IR from baseline respectively after 4 weeks of daily oral dosing of DUR-928. Subjects in the 600 mg group did not show a change in HOMA-IR.
- **Improvement from baseline in liver stiffness**, assessed by transient elastography (TE), magnetic resonance elastography (MRE) and the liver fibrosis marker pro-C3.
- Previously reported data showed improvement from baseline in: **liver enzymes** such as ALT, AST and GGT and improvements in serum lipid profiles such as LDL-C, non-HDLC and triglycerides; **liver fat** by MRI-PDFF imaging; and **biomarkers of liver health**, such as CK-18, a cell death biomarker, certain of which were statistically significant improvements.
- **Safety profile:** DUR-928 was safe and well tolerated by all subjects in the study.

Data highlights from Poster #668 entitled “Safety and Pharmacokinetics of DUR-928 in Hepatic Function Impaired Subjects,” presented by Jaymin Shah, Ph.D., Executive Director, Clinical Pharmacology and Pharmacokinetics at DURECT, included:

- **Safety profile:** DUR-928 was safe and well-tolerated by all moderate and severe hepatic impairment (HI) subjects with no adverse events and no dose-limiting toxicity reported throughout the study.
- **Pharmacokinetics:** As expected, clearance of DUR-928 was decreased in HI subjects compared to matched control subjects with normal hepatic function, leading to a 4-10 fold higher drug exposure (C<sub>max</sub> and AUC) in HI subjects depending on the severity of HI.
- **Initial efficacy signals:** A single oral dose of 200 mg of DUR-928 in subjects with HI resulted in statistically significant median reductions from baseline of the apoptosis biomarker M30 (cCK-18) at 12 hours post-dose.

Copies of the posters will be available on DURECT's corporate website [here](#) at the conclusion of the conference.

#### **About the DUR-928 NASH Phase 1b Trial**

The Phase 1b study was a randomized, open-label, multi-center U.S. study to evaluate safety, pharmacokinetics and signals of biological activity of DUR-928 in NASH subjects with stage 1-3 fibrosis. A total of 65 patients completed the study. DUR-928 was orally administered daily at 50 mg (n=23), 150 mg (n=21), or 600 mg (300 mg BID (n=21)) for 4 weeks and followed up for an additional 4 weeks.

#### **About the DUR-928 Phase 1 Trial in Hepatic Liver Impairment**

The Phase 1 study was an open-label, multi-center U.S. study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of DUR-928 in subjects with moderate (Child-Pugh B scores) and severe (Child-Pugh C scores) hepatic impairment, who received a single oral dose of 200 mg DUR-928.

#### **About DUR-928**

DUR-928 is an endogenous sulfated oxysterol and an epigenetic regulator. Epigenetic regulators are compounds that regulate patterns of gene expression without modifying the DNA sequence. DNA hypermethylation, an example of epigenetic dysregulation, results in transcriptomic reprogramming and cellular dysfunction, and has been found to be associated with many acute (e.g., AH) or chronic diseases (e.g., NASH). As an inhibitor of DNA methyltransferases (DNMT1, DNMT3a and 3b), DUR-928 inhibits DNA methylation, which subsequently regulates expression of genes that are involved in cell signaling pathways associated with stress responses, cell death and survival, and lipid biosynthesis. This may ultimately lead to improved cell survival, reduced inflammation, and decreased lipotoxicity. As an epigenetic regulator, the proposed mechanism of action provides further scientific rationale for developing DUR-928 for the treatment of acute organ injury and certain chronic diseases.

#### **About Epigenetic Regulation**

Epigenetic regulation influences the expression of genes through the silencing or initiation of gene activity without modifying the DNA sequence. For instance, methylation of cytosine nucleotides in promoter regions of DNA, facilitated by DNA methyltransferases (DNMTs), will generally result in downregulation of gene expression, while demethylation generally results in upregulation. DNA methylation/demethylation can thus regulate the expression of relevant genes, especially clusters of master genes that further modulate crucial cellular activities.

#### **About DURECT Corporation**

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted

a Fast Track Designation. The Company is conducting a double-blind, placebo-controlled Phase 2b clinical trial called AHFIRM, evaluating DUR-928's lifesaving potential compared to the current standard of care in patients with severe AH. Non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is now FDA-approved. Full prescribing information about POSIMIR, including the Boxed Warning, can be found at [www.posimir.com](http://www.posimir.com). For more information about DURECT, please visit [www.durect.com](http://www.durect.com) and follow us on Twitter <https://twitter.com/DURECTCorp>.

### **DURECT Forward-Looking Statement**

The statements in this press release regarding the potential for DUR-928 to treat patients with AH, NASH, HI and other diseases, such as acute organ injury, its potential to reduce HOMA-IR, ongoing and planned clinical trials of DUR-928, and the commercial potential of POSIMIR are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that the clinical trial of DUR-928 in AH (AHFIRM) takes longer to conduct than anticipated due to COVID-19 or other factors, the risk that clinical trials of DUR-928, including AHFIRM, do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy or the lifesaving potential of DUR-928 in a statistically significant manner, risks that we or a third-party licensee may not commercialize POSIMIR successfully, if at all, and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on May 5, 2021 under the heading "Risk Factors."

NOTE: POSIMIR® and SABER® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. DUR-928 is an investigational drug candidate under development and has not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication. Full prescribing information for POSIMIR, including its Boxed Warning, can be found at [www.posimir.com](http://www.posimir.com).

**SOURCE:** DURECT Corporation

#### **Corporate Contact**

Mike Arenberg

DURECT

Chief Financial Officer

+1-408-346-1052

[mike.arenberg@durect.com](mailto:mike.arenberg@durect.com)

#### **Media Contact**

Mónica Rouco Molina, Ph.D.

LifeSci Communications

+1-929-469-3850

[mrroucomolina@lifescicomms.com](mailto:mrroucomolina@lifescicomms.com)